Publications

Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives  (2011)

Authors:
Dalla Pozza E; Donadelli M; Costanzo C; Zaniboni T; Dando I; Franchini M; Arpicco S; Scarpa A; Palmieri M
Title:
Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives
Year:
2011
Type of item:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Nations of authors:
ITALIA
Language:
Inglese
Format:
A Stampa
Referee:
Name of journal:
Free Radical Biology and Medicine
ISSN of journal:
0891-5849
N° Volume:
50
Number or Folder:
8
Page numbers:
926-933
Code PMID:
21236335
Keyword:
pancreatic adenocarcinoma, gemcitabine, zinc, dithiocarbamate, oxidative stress, apoptosis
Short description of contents:
Pancreatic adenocarcinoma is a common malignancy that remains refractory to all available therapies, including the gold standard drug gemcitabine (GEM). We investigated the effect of the combination between GEM and the ionophore compounds pyrrolidine dithiocarbamate (PDTC) or disulfiram [DSF, 1-(diethylthiocarbamoyldisulfanyl)-N,N-diethyl-methanethioamide] on p53(-/-) pancreatic adenocarcinoma cell growth. PDTC or DSF synergistically inhibited cell proliferation when used in combination with GEM by inducing apoptotic cell death. This effect was associated to an increased mitochondrial O(2)(.-) production and was further enhanced by zinc ions. Basal levels of mitochondrial O(2)(.-) or manganese superoxide dismutase (MnSOD) strictly correlated with the IC(50) for GEM or the percentage of synergism. Thus, the most relevant values of the antiproliferative synergism were obtained in GEM-resistant pancreatic adenocarcinoma cell lines. Interestingly, the GEM-sensitive T3M4 cells transfected with MnSOD expression vector showed mitochondrial O(2)(.-) and IC(50) for GEM similar to those of resistant cell lines. In vivo experiments performed on nude mice xenotransplanted with the GEM-resistant PaCa44 cell line showed that only the combined treatment with GEM and DSF/Zn completely inhibited the growth of the tumoral masses. These results and the consideration that DSF is already used in clinics strongly support GEM and DSF/Zn combination as a new approach to overcome pancreatic cancer resistance to standard chemotherapy.
Web page:
http://preview.ncbi.nlm.nih.gov/pubmed/21236335
Product ID:
58831
Handle IRIS:
11562/347594
Deposited On:
February 29, 2012
Last Modified:
November 23, 2016
Bibliographic citation:
Dalla Pozza E; Donadelli M; Costanzo C; Zaniboni T; Dando I; Franchini M; Arpicco S; Scarpa A; Palmieri M, Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives «Free Radical Biology and Medicine» , vol. 50 , n. 82011pp. 926-933

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo IRIS

Related projects
Title Department Managers
<<back

Activities

Research facilities